EMD Serono Newsroom

To keep up with the latest news in real-time, subscribe to our email alerts, and follow us on Twitter, Facebook and LinkedIn. If you are a reporter and have questions about the company, please contact us

Latest News

 

Oct 12, 2018

First Bruton’s Tyrosine Kinase inhibitor (BTKi) demonstrating clinical proof-of-concept in relapsing multiple sclerosis (RMS) Study met primary endpoint demonstrating significant reduction in...

Oct 11, 2018

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the publication of results from a global Company-sponsored multiple sclerosis...

Oct 10, 2018

Real-world evidence and longer clinical trial follow-up show no increased incidence of serious adverse events Additional post-hoc data analyses support sustained efficacy of cladribine tablets in...

Oct 9, 2018

First presentation of Phase III data for avelumab (plus axitinib) in previously untreated, advanced kidney cancer New and updated data for bifunctional immunotherapy M7824 Results from Phase II...

  All Press Releases